Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a
company focused on developing, marketing, and selling a variety of
men’s health and wellness products via a secure telemedicine
platform, including its uniquely formulated erectile dysfunction
(ED) drug branded “Mango,” today announced the official commercial
launch of its second Mango ED product, which leverages the
Company’s existing custom compound alongside Sildenafil, the active
ingredient found in Viagra™.
Interested consumers can now proceed through the
Company’s telemedicine platform and select either a
Sildenafil-based Mango or the Company’s original Tadalafil-based
Mango ED product, which leverages the active ingredient found in
Cialis™. Both the Sildenafil and Tadalafil-based Mango ED products
are compounded with Oxytocin and L-Arginine in a tasty
Mango-flavored, rapid dissolve tablet (RDT) and individually
packaged in a master pack of six tablets per package.
“With the launch of our new Sildenafil-based
Mango ED product, we can harness the power of the two most popular
and successful erectile dysfunction drugs developed over the past
two decades and pair them with our own proprietary formulation in a
faster-acting, better-tasting ED solution,” remarked Jacob Cohen,
CEO and Co-Founder of MangoRx. “Each of these compounds has already
cultivated its own sizeable following and both can be effectively
integrated into our proprietary blend and delivery mechanism.”
Management notes that Tadalafil and Sildenafil
each have their own unique properties, which can lead to different
manifest effects among users. For example, Tadalafil has been
proven to last longer than Sildenafil due to a half-life more than
four times as long. At the same time, Sildenafil may reach full
efficacy faster than Tadalafil.
Cohen added, “Perhaps the most important point
here is that we are standing on the shoulders of billions of
dollars of prior marketing spend. And we have spent the past six
months building a huge marketing footprint of our own through our
investments in high-traffic, high-relevance podcasts and other
highly visible media appearances, interviews, and ads, as well as
our own viral marketing and advertising efforts. Now we can pair
this visibility with a stable of currently available,
market-leading products to drive strong sales growth in the second
half of the year.”
About Mango
Created using a special formulation featuring
either the same active ingredient as in Cialis™ (Tadalafil) or
Viagra™ (Sildenafil), each part of the Mango formulation plays a
critical role in helping men achieve optimum performance. We
believe the key to our success lies in our unique blend of
ingredients, which are used in U.S. Food and Drug Administration
(“FDA”) approved drugs. Mango contains a combination of either
Sildenafil or Tadalafil along with Oxytocin and L-Arginine that
have been traditionally used to treat sexual dysfunction.
Mango is a prescription medication that must be
approved by a physician. After an individual has completed an
online tele-health visit, our network of medical providers will
review and approve a prescription if medically appropriate. Mango
is a rapidly dissolved tablet (RDT) that is absorbed orally. For
best results, we advise taking Mango at least 15 minutes before
engaging in sexual activity. Sildenafil and Tadalafil, one of the
main ingredients in Mango, typically have effects that last up to 4
and 36 hours, respectively.
About Mangoceuticals
Mangoceuticals, Inc. is a company focused on
developing, marketing, and selling a variety of men's health and
wellness products and services via a secure telemedicine platform.
To date, the Company has identified men's wellness telemedicine
services and products as a growing sector and especially related to
the area of erectile dysfunction (ED). The Company has developed a
new brand of ED product under the brand name "Mango" (think: "Man,
Go!").
For more information, please visit
www.MangoRx.com.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws, including within the meaning of the
Private Securities Litigation Reform Act of 1995 ("forward-looking
statements"). These forward-looking statements represent the
Company's current expectations or beliefs concerning future events
and can generally be identified using statements that include words
such as "estimate," "expects," "project," "believe," "anticipate,"
"intend," "plan," "foresee," "forecast," "likely," "will," "target"
or similar words or phrases. These forward-looking statements are
subject to risks, uncertainties and other factors, many of which
are outside of the Company's control which could cause actual
results to differ materially from the results expressed or implied
in the forward-looking statements, including, but not limited to;
our ability to obtain additional funding and generate revenues to
support our operations; risks associated with our ED product which
have not been, and will not be, approved by the U.S. Food and Drug
Administration ("FDA") and have not had the benefit of the FDA's
clinical trial protocol which seeks to prevent the possibility of
serious patient injury and death; risks that the FDA may determine
that the compounding of our planned products does not fall within
the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA
Act") provided by Section 503A; risks associated with related party
relationships and agreements; the effect of data security breaches,
malicious code and/or hackers; competition and our ability to
create a well-known brand name; changes in consumer tastes and
preferences; material changes and/or terminations of our
relationships with key parties; significant product returns from
customers, product liability, recalls and litigation associated
with tainted products or products found to cause health issues; our
ability to innovate, expand our offerings and compete against
competitors which may have greater resources; our significant
reliance on related party transactions; the projected size of the
potential market for our technologies and products; risks related
to the fact that our Chairman and Chief Executive Officer, Jacob D.
Cohen, has majority voting control over the Company; risks related
to the significant number of shares in the public float, our share
volume, the effect of sales of a significant number of shares in
the marketplace, and the fact that the majority of our shareholders
paid less for their shares than the public offering price of our
common stock in our recent initial public offering; the fact that
we have a significant number of outstanding warrants to purchase
shares of common stock at $1.00 per share, the resale of which
underlying shares have been registered under the Securities Act of
1933, as amended; our ability to build and maintain our brand;
cybersecurity, information systems and fraud risks and problems
with our websites; changes in, and our compliance with, rules and
regulations affecting our operations, sales, marketing and/or our
products; shipping, production or manufacturing delays; regulations
we are required to comply with in connection with our operations,
manufacturing, labeling and shipping; our dependency on
third-parties to prescribe and compound our ED product; our ability
to establish or maintain relations and/or relationships with
third-parties; potential safety risks associated with our Mango ED
product, including the use of ingredients, combination of such
ingredients and the dosages thereof; the effects of high inflation,
increasing interest rates and economic downturns, including
potential recessions, as well as macroeconomic, geopolitical,
health and industry trends, pandemics, acts of war (including the
ongoing Ukraine/Russian conflict) and other large-scale crises; our
ability to protect intellectual property rights; our ability to
attract and retain key personnel to manage our business
effectively; our ability to maintain the listing of our common
stock on the Nasdaq Capital Market; overhang which may reduce the
value of our common stock; volatility in the trading price of our
common stock; and general consumer sentiment and economic
conditions that may affect levels of discretionary customer
purchases of the Company's products, including potential recessions
and global economic slowdowns. Although we believe that our plans,
intentions and expectations reflected in or suggested by the
forward-looking statements we make in this release are reasonable,
we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties.
More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended March 31, 2023. These
filings are available at www.sec.gov and at our website at
https://investors.mangorx.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow Mangoceuticals and MangoRx on social
media: https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial
Or just click here to see why Orange is the new
Blue: https://www.mangorx.com
FOR PUBLIC RELATIONS Lucky Break Public
Relations MangoRX@luckybreakpr.com (323) 602-0091 ext. 704
FOR INVESTOR RELATIONS Mangoceuticals Investor
Relations Email: investors@mangorx.com
MEDIA CONTACT PHOENIX MGMT Marketing &
Consulting info@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.
Mangoceuticals (NASDAQ:MGRX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Mangoceuticals (NASDAQ:MGRX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024